Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Aug 29;12(2):123–134. doi: 10.1111/j.1527-3458.2006.00123.x

Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor

Phil Skolnick 1,✉, Philip Krieter 1, Joseph Tizzano 1, Anthony Basile 1, Piotr Popik 2, Pal Czobor 1, Arnold Lippa 1
PMCID: PMC6494125  PMID: 16958986

ABSTRACT

DOV 216,303 [(±)‐1‐(3,4‐dichlorophenyl)‐3‐azabicyclo‐[3.1.0]hexane hydrochloride] is the prototype of a class of compounds referred to as “triple” reuptake inhibitors. Such compounds inhibit the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), the three neurotransmitters most closely linked to major depressive disorder. DOV 216,303 inhibits [3H]NE, [3H]5‐HT, and [3H]DA uptake to the corresponding human recombinant transporters (expressed in HEK 293 cells) with IC50 values of ∼20, 14, and 78 nM, respectively. DOV 216,303 is active in tests predictive of antidepressant activity including the mouse forced swim test and reversal of tetrabenazine‐induced ptosis and locomotor depression. The pharmacodynamic, pharmacokinetic, and toxicological profile of DOV 216,303 in animals prompted us to initiate clinical studies. In both single and multiple dose studies using normal volunteers, DOV 216,303 was safe and well‐tolerated. Furthermore, both Cmax and AUC values were dose‐proportional between 5–150 mg. The plasma concentrations of DOV 216,303 at doses >10 mg were in excess of the IC50 values for inhibition of biogenic amine reuptake. In a Phase II study designed to explore the safety and tolerability of DOV 216,303 in depressed individuals, patients received either 100 mg DOV 216,303 (50 mg b.i.d.) or 40 mg citalopram (20 mg, b.i.d.) for two weeks. A placebo arm was not employed in this study because several institutional review boards required administration of an active control to severely depressed individuals. Time dependent reductions in HAM‐D scores (the primary outcome measure) were observed in both the DOV 216,303 and citalopram groups compared to baseline scores (p < 0.0001). The side effect profile was not remarkably different between treatment arms. These findings provide preliminary evidence of a clinically meaningful antidepressant action with a molecule capable of inhibiting the three transmitters most closely linked to major depressive disorder.

Keywords: Antidepressants; Depression; DOV 216,303; Neurotransmitter uptake inhibitors

Full Text

The Full Text of this article is available as a PDF (123.4 KB).

REFERENCES

  • 1. Beer B, Stark J, Kreiter P, et al. DOV 216,303, a “triple” reuptake inhibitor: Safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44: 1360–1367. [DOI] [PubMed] [Google Scholar]
  • 2. Bodkin JA, Lasser RA, Wines JD, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58: 137–145. [DOI] [PubMed] [Google Scholar]
  • 3. D'Aquila PS, Collu M, Gessa GL, et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000;405: 365–373. [DOI] [PubMed] [Google Scholar]
  • 4. Fava M. Augmentation and combination strategies in treatment‐resistant depression. J Clin Psychiatry 2001;62(Suppl 18):4–11. [PubMed] [Google Scholar]
  • 5. Inoue T, Tscuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant‐resistant depression. Biol Psychiatry 1996;40: 151–153. [DOI] [PubMed] [Google Scholar]
  • 6. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant‐resistant depression. J Affect Disord 2000;61: 127–132. [DOI] [PubMed] [Google Scholar]
  • 7. Kelley AE. Neural integrative activities of nucleus accumbens subregions in relation to learning and motivation. Psychobiology 1999;27: 198–213. [Google Scholar]
  • 8. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2000;63: 181–186. [DOI] [PubMed] [Google Scholar]
  • 9. Lammers C‐H, Diaz J, Schwartz J‐C, et al. S elective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000;5: 378–388. [DOI] [PubMed] [Google Scholar]
  • 10. Learned‐Coughlin S, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003;54: 800–805. [DOI] [PubMed] [Google Scholar]
  • 11. Li S, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002;42: 181–190. [DOI] [PubMed] [Google Scholar]
  • 12. Maj J, Rogoz Z. Synergistic effects of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol 1999;51: 471–475. [PubMed] [Google Scholar]
  • 13. Meyer, JH , Wilson AA, Sagrati S, et al. S erotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161: 826–835. [DOI] [PubMed] [Google Scholar]
  • 14. Montgomery SA, Djarv L. The antidepressant efficacy of citalopram. Int Clin Psychopharmacol 1996; 11(Suppl 1):29–33. [DOI] [PubMed] [Google Scholar]
  • 15. Naranjo C, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001;25: 781–823. [DOI] [PubMed] [Google Scholar]
  • 16. Nelson JC. Augmentation strategies with serotonergic‐noradrenergic combinations. J Clin Psychiatry 1998;59: 65–68. [PubMed] [Google Scholar]
  • 17. Popik P, Krawczyk M, Golembiowska K, et al. Pharmacological profile of the “triple” reuptake inhibitor, DOV 102,677. Chem Mol Neurobiol 2006; In press. [DOI] [PubMed] [Google Scholar]
  • 18. Povlock SL, Amara SG. The structure and function of norepinephrine, dopamine and serotonin transporters In: Reith MEA, Ed. Neurotransmitter transporters: Structure, function, and regulation. Totowa : Humana Press, 1997; 1–28. [Google Scholar]
  • 19. Skolnick P. Antidepressants Skolnick P, Ed. New Pharmacological Strategies. Totowa : Humana Press, 1997. [Google Scholar]
  • 20. Skolnick P, Legutko B, Li X, et al. Current perspectives on the development of non‐biogenic amine‐based antidepressants. Pharmacol Res 2001;43: 411–422. [DOI] [PubMed] [Google Scholar]
  • 21. Skolnick P. Dopamine and depression In: Schmidt W, Ed. Dopamine and glutamate in psychiatric disorders. Totowa : Humana Press, 2005;9: 199–214. [Google Scholar]
  • 22. Skolnick P, Popik P, Janowsky A, et al. Broad spectrum” antidepressants: Is more better for the treatment of depression Life Sci 2003;73: 3175–3179. [DOI] [PubMed] [Google Scholar]
  • 23. Skolnick P, Popik P, Janowsky A, et al. Antidepressant‐like actions of DOV 21,947: A “triple” reuptake inhibitor. Eur J Pharmacol 2003;461: 99–104. [DOI] [PubMed] [Google Scholar]
  • 24. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: A retrospective chart review. Ann Clin Psychiatry 2000;12: 137–140. [DOI] [PubMed] [Google Scholar]
  • 25. Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55: 320–322. [DOI] [PubMed] [Google Scholar]
  • 26. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: A 10‐year review and evaluation. Psychopharmacology 1997;134: 319–329. [DOI] [PubMed] [Google Scholar]
  • 27. Willner P, Papp M. Animal Models to Detect Antidepressants In: Antidepressants: Skolnick P, Ed. New pharmacological strategies. Totowa : Humana Press, 1997;213–234. [Google Scholar]
  • 28. Wise RA. Brain reward circuity: Insights from unsensed incentives. Neuron 2002;36: 229–240. [DOI] [PubMed] [Google Scholar]
  • 29. Zisook S, Rush JA, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2005;59: 203–210. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES